Search Results

Origin Life Sciences, Inc. announced that the Company’s abstract, titled: “NO: a Novel, Pathogen-Agnostic Therapy for Treatment-Resistant Wound Infections in the Warfighter,” has been accepted for presentation at 2024 Military Health System Research Symposium.

Thermo Fisher Scientific Inc., the world leader in serving science, has introduced the Gibco™ CTS™ OpTmizer™ One Serum-Free Medium *, a novel animal origin-free formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion.

Vera Therapeutics, Inc. announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy, showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria.

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, and the Cell and Gene Therapy Catapult, an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, announced a collaboration to demonstrate universal automation of CGT manufacturing.

Aadi Bioscience, Inc. announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor had gynecologic origins experienced efficacy and safety consistent with the overall study population.

PharmaTher Holdings Ltd. announced receipt of an Amendment Acknowledgment Letter for its Priority Original Abbreviated New Drug Application for Ketamine from the U.S. Food and Drug Administration and assigned a Generic Drug User Fee Amendments of 2022 goal date of October 29, 2024.

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, announced the appointment of Peter Crossley as Chief Operating Officer.